Shares of West Pharmaceutical Services Inc. soared in pre-market trading on Thursday, after the medical device company reported better-than-expected third-quarter earnings and raised its full-year guidance.
For the third quarter of 2024, West Pharmaceutical posted adjusted earnings per share of $1.85, beating the consensus estimate of $1.50 among analysts. The company's revenue of $746.9 million also topped Wall Street's projection of $709.616 million.
Following the strong quarterly results, West Pharmaceutical raised its full-year 2024 net sales guidance to a range of $2.875 billion to $2.905 billion, compared to its prior guidance of $2.87 billion to $2.9 billion and the consensus estimate of $2.874 billion.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。